Shield Therapeutics PLC Notice of Results (8030Y)
14 September 2020 - 4:00PM
UK Regulatory
TIDMSTX
RNS Number : 8030Y
Shield Therapeutics PLC
14 September 2020
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Notice of Results
Analyst and Investor Briefings
London, UK, 14 September 2020: Shield Therapeutics plc (LSE:
STX), a commercial stage, pharmaceutical company with a focus on
addressing iron deficiency with its lead product Feraccru (R)
/Accrufer (R) (ferric maltol), will announce its interim results
for the six months ended 30 June 2020 on Wednesday 16 September
2020.
Analyst briefing
A briefing open to analysts will take place remotely via video
conference call on Wednesday 16 September 2020 at 11.00am. If you
would like the details of this call please contact Walbrook PR on
shield@walbrookpr.com .
Investor briefing
Shield Therapeutics will be hosting a live online presentation
open to all investors on Wednesday 16 September at 4.30pm. The
Company is committed to providing an opportunity for all existing
and potential investors to hear directly from management on the
recent developments and additionally providing an update on the
business.
The presentation will be hosted through the digital platform
Investor Meet Company. Investors can sign up to Investor Meet
Company for free and add to meet Shield Therapeutics plc via the
following link:
https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor
For those investors who have already registered and added to
meet the Company, they will automatically be invited.
Questions can be submitted pre-event via your Investor Meet
Company dashboard or in real time during the presentation, via the
"Ask a Question" function. Whilst the Company may not be in a
position to answer every question it receives, it will aim to
address the most prominent within the confines of information
already disclosed to the market through regulatory notifications. A
recording of the presentation, a PDF of the slides used, and
responses to the Q&A session will be available on the Investor
Meet Company platform afterwards.
For further information please contact:
Shield Therapeutics plc www.shieldtherapeutics.com
Tim Watts, CEO +44 (0)20 7186 8500
Karen Chandler Smith, Investor
Relations
Nominated Adviser and Joint
Broker
Peel Hunt LLP
James Steel/Dr Christopher
Golden +44 (0)20 7418 8900
Joint Broker
finnCap Ltd
Geoff Nash/Matt Radley/Alice
Lane +44 (0)20 7220 0500
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391
Paul McManus/Lianne Cawthorne 303
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused
on commercialising its lead product, Feraccru(R)/Accrufer(R), a
novel, stable, non-salt based oral therapy for adults with iron
deficiency with or without anaemia. Feraccru(R)/Accrufer(R) has
been approved for use in the United States, European Union, UK and
Switzerland and has exclusive IP rights until the mid-2030s.
Feraccru is commercialised in the UK and Europe by Norgine B.V. and
the Company is currently in the process of selecting a
commercialisation partner for the US market. Shield also has an
exclusive licence agreement with Beijing Aosaikang Pharmaceutical
Co., Ltd., for the development and commercialisation of
Feraccru(R)/Accrufer(R) in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com .
Follow Shield on Twitter @ShieldTx
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORBUGDCSDBDGGB
(END) Dow Jones Newswires
September 14, 2020 02:00 ET (06:00 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Apr 2024 to May 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From May 2023 to May 2024